Abstract-Obesity is often associated with reduced plasma insulin-like growth factor 1 (IGF-1) levels, oxidative stress, mitochondrial damage, and cardiac dysfunction. This study was designed to evaluate the impact of IGF-1 on high-fat diet-induced oxidative, myocardial, geometric, and mitochondrial responses. FVB and cardiomyocyte-specific IGF-1 overexpression transgenic mice were fed a low-(10%) or high-fat (45%) diet to induce obesity. High-fat diet feeding led to glucose intolerance, elevated plasma levels of leptin, interleukin 6, insulin, and triglyceride, as well as reduced circulating IGF-1 levels. Echocardiography revealed reduced fractional shortening, increased end-systolic and end-diastolic diameter, increased wall thickness, and cardiac hypertrophy in high-fat-fed FVB mice. High-fat diet promoted reactive oxygen species generation, apoptosis, protein and mitochondrial damage, reduced ATP content, cardiomyocyte cross-sectional area, contractile and intracellular Ca 2ϩ dysregulation (including depressed peak shortening and maximal velocity of shortening/ relengthening), prolonged duration of relengthening, and dampened intracellular Ca 2ϩ rise and clearance. Western blot analysis revealed disrupted phosphorylation of insulin receptor and postreceptor signaling molecules insulin receptor substrate 1 (tyrosine/serine phosphorylation), Akt, glycogen synthase kinase 3␤, forkhead transcriptional factors, and mammalian target of rapamycin, as well as downregulated expression of mitochondrial proteins peroxisome proliferator-activated receptor-␥ coactivator 1␣ and uncoupling protein 2. Intriguingly, IGF-1 mitigated high-fat-diet feeding-induced alterations in reactive oxygen species, protein and mitochondrial damage, ATP content, apoptosis, myocardial contraction, intracellular Ca 2ϩ handling, and insulin signaling but not whole body glucose intolerance and cardiac hypertrophy. Exogenous IGF-1 treatment also alleviated high-fat diet-induced cardiac dysfunction. Our data revealed that IGF-1 alleviates high-fat diet-induced cardiac dysfunction despite persistent cardiac remodeling, possibly because of preserved cell survival, mitochondrial function, and insulin signaling. (Hypertension. 2012;59:00-00.) • Online Data Supplement Key Words: IGF-1 Ⅲ high fat Ⅲ heart Ⅲ oxidative stress Ⅲ insulin signaling Ⅲ mitochondrial function U ncorrected obesity and associated anomalies, such as type 2 diabetes mellitus, hypertension, and atherogenic dyslipidemia, are among major risk factors contributing to myocardial dysfunction and remodeling, leading to high cardiovascular morbidity and mortality. 1-3 Although several scenarios including oxidative stress, endoplasmic reticulum stress, apoptosis, and dyslipidemia have been implicated in obesity-related pathophysiological changes in the heart, 2-6 none of the aforementioned conditions is considered the ultimate culprit for obesity cardiomyopathy. To better understand the mechanism behind cardiac anomalies in obesity, a fat-enriched diet is used to induce diet-induced prediabetic normotensive or mildly hypertensive obesity. 6,7 Recent evidence from our laboratory, as well as others, depicted that diet-induced obesity is accompanied by insulin resistance, inflammation, apoptosis, cardiac hypertrophy, myocardial dysfunction, downregulated mitochondrial oxidative phosphorylation, and biogenesis. 6 -9 Nonetheless, the precise pathogenesis of cardiac hypertrophy and contractile dysfunction, in particular, the interaction between the two, remains elusive in high-fat diet-induced obesity.
Ample clinical and experimental reports have indicated that obesity and the fat mass-and obesity-associated genes are closely related to reduced levels of growth hormone and its hepatic metabolic product insulin-like growth factor 1 (IGF-1). 10 -12 The diminished growth hormone secretion may be accompanied by overtly elevated levels of reactive oxygen species (ROS) and reduced lean body mass in obesity. 2, 9, 10, 13 Thus, the present study was undertaken to examine the impact of overexpression of IGF-1, an essential cardiac survival factor, 14 on high-fat diet-induced cardiac geometric, morphological, and functional defects. In an effort to elucidate the cellular mechanisms underscoring IGF-1-and high-fat dietinduced myocardial alterations, if any, special attention was paid to insulin signaling, apoptosis, mitochondrial integrity including ATP content, cytochrome C release, peroxisome proliferator-activated receptor-␥ coactivator 1␣ (PGC1␣), and uncoupling protein 2 (UCP-2). PGC1␣ activates mitochondrial biogenesis and increases oxidative phosphorylation by facilitating transcription, translation, and activation of transcription factors necessary for mitochondrial DNA replication. 8 PGC1␣-stimulated mitochondrial biogenesis and respiration are believed to be mediated through UCP-2, which plays a crucial role in the control of ROS production. 15, 16 Given that insulin/IGF-1 receptors, insulin receptor substrate-1 (IRS-1), Akt, glycogen synthase kinase 3␤ (GSK3␤), forkhead transcriptional factors (Foxo3a), and mammalian target of rapamycin (mTOR) are pivotal in the shared insulin/IGF-1 signaling, 17, 18 insulin signaling at the receptor and postreceptor levels, including IRS-1 phosphorylation (tyrosine 1146 and serine 307), 19, 20 was assessed after high-fat diet feeding in wild-type FVB and cardiomyocytespecific IGF-1 transgenic mice. To evaluate the role of insulin signaling degradation phosphatases, 21 levels of protein phosphatases 2A and 2B (PP2A/PP2B) were monitored in FVB and IGF-1 mouse hearts. In an effort to elucidate the cellular mechanisms behind IGF-1 overexpression and/or high-fat diet-induced myocardial functional alterations, expression of intracellular Ca 2ϩ regulatory proteins, including sarco(endo) plasmic reticulum Ca 2ϩ-ATPase (SERCA2a), Na ϩ -Ca 2ϩ exchanger, and phospholamban, was scrutinized. Given the key roles of ubiquitin proteosome, inflammation, and hypertrophic factor nuclear factor of activated T cells in the regulation of cardiac remodeling and contractile function, [22] [23] [24] ubiquitin, tumor necrosis factor (TNF)-␣ and nuclear factor of activated T cells c3 were evaluated in FVB and IGF-1 hearts after high-fat diet feeding.
Materials and Methods
Please refer to the online-only Data Supplement for a full Methods description.
Experimental Animals, High-Fat Feeding, and Plasma Tests
The experimental procedure described here was approved by the institutional animal use and care committee at the University of Wyoming. In brief, 2-to 3-month-old male FVB and cardiomyocyte-specific IGF-1 transgenic mice were randomly assigned to low-fat (10% of total calorie) or high-fat (45% of total calorie) diets for 5 months. Generation of IGF-1 mice was described previously. 25 Mice were housed in a climate-controlled environment with a 12-hour/12-hour light/dark cycle and free access to diets and water.
After 5 months of feeding, intraperitoneal glucose tolerance test was evaluated. 26 Plasma insulin, interleukin 6, leptin, IGF-1, and triglycerides levels; blood pressure; and myocardial IGF-1 levels were determined. 27, 28 A cohort of low-fat and high-fat-fed FVB mice was treated with recombinant IGF-1 (3 mg/kg per day, IP) for 8 weeks after being placed on low-and high-fat diets for 3 months. 29 
Echocardiographic Assessment
Cardiac geometry and function were evaluated in anesthetized mice using a 2D guided M-mode echocardiography equipped with a 15-MHz linear transducer. 9 
Isolation of Murine Cardiomyocytes, Cell Culture, and Cell Mechanics
After ketamine/xylazine sedation, hearts were removed and digested with collagenase D (223 U/mL). 26 Cells were maintained in DMEM at 37°C for 6 hours for in vitro study. Mechanical and intracellular Ca 2ϩ properties of cardiomyocytes were assessed using an IonOptix soft-edge system. 26 
ROS Production, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetrazolium Bromide, Caspase 3, TUNEL Assay, and Lipid Peroxidation
Cardiomyocyte ROS was evaluated using the intracellular fluoroprobe 5-6-chloromethyl-2Ј,7Ј-dichlorodihydrofluorescein diacetate. 30 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay was performed to determine cardiomyocyte cell viability. 31 Caspase 3 activity was measured in tissue homogenates using the colorimetric substrate Ac-DEVD-pNA. 17 TUNEL staining of myonuclei positive for DNA strand breaks was determined in the myocardium using a fluorescence detection kit and fluorescence microscopy. 17 The lipid peroxidation end products malondialdehyde and 4-hydrononenal levels were measured in myocardial homogenates using a colorimetric assay. 27 Aconitase Activity, Cytochrome C Release, and ATP Content in Myocardium Aconitase activity was determined using an Aconitase assay kit. 7 Cytochrome C content was determined in mitochondria and fractions using Western blot analysis with the anticytochrome C antibody. 17 ATP content was determined using the Grace Partisil SAX column chromatography. 32 
Histological Examination
Specimens were processed and embedded in paraffin. Deparaffinized slides were briefly rinsed in PBS and incubated in fluorescein isothiocyanate-tagged lectin. Cardiomyocyte cross-sectional areas were digitalized using an Olympus BX-51 microscope equipped with a fluorescence filter and measured with the Image J software. 33 
Western Blot Analysis
Myocardial protein was prepared as described. 17 The anti-PGC1␣, antiphosphorylated IRS (Ser307 or Tyr1146), anti-IRS, anti-GSK3␤, antiphosphorylated GSK3␤ (Ser9), anti-Akt, antiphosphorylated Akt, (Thr308), antiphosphorylated Foxo3a (Thr32), anti-Foxo3a, antiphosphorylated mTOR (Ser2448), anti-mTOR, anti-Bax, antiphosphorylated Bad (Ser112), anti-Bad, antinuclear factor of activated T cells c3, anti-PP2A, anti-PP2B, anti-GAPDH (loading control; 1:1000, Cell Signaling), anti-SERCA2a (1:1000, Affinity Bioreagents Inc), anti-Na ϩ -Ca 2ϩ exchanger (1:1000, Sigma), antiphospholamban (1:500, Abcam), anti-UCP-2, anti-Bcl-2, antiubiquitin, and antiphosphotyrosine (1:200, Santa Cruz) antibodies were used for Western blotting. Samples containing equal amount of proteins were separated on 10% or 15% SDS-polyacrylamide gels in a minigel apparatus. After immunoblotting, the film was scanned, and the intensity of immunoblot bands was detected with a Bio-Rad Calibrated Densitometer.
Immunoprecipitation
Co-IP assay was performed following the protocol of the Co-IP kit (Pierce). Briefly, 50 g of purified IR and IGF-1 receptor-␤ antibodies were immobilized with coupling resin. Protein extracts (500 g) were incubated with antibody-coupled resin gently endover-end mixing for 2 hours at room temperature. The resin was washed, and the protein complexes bound to the antibody were eluted with 50 L of elution buffer. The eluted protein was boiled and separated by 10% SDS-PAGE, transferred to a nitrocellulose membrane, and incubated with antiphosphotyrosine antibody. Antibody binding was detected using the enhanced chemiluminescence. The film was scanned and the intensity of immunoblot bands was detected with a Bio-Rad Calibrated Densitometer (model GS-800). 34 
Glucose Uptake Assay
Cardiomyocytes were washed 3 times with Krebs-Ringer-HEPES (KRH; 136.00 mmol/L of NaCl, 4.70 mmol/L of KCl, 1.25 mmol/L of CaCl 2 , 1.25 mmol/L of MgSO 4 , and 10 mmol/L of HEPES; pH 7.4) buffer and incubated with 2 mL of KRH buffer at 37°C for 30 minutes. A cohort of cardiomyocytes from each group was subject to insulin stimulation (10 nmol/L; 15 minutes). Glucose uptake was initiated with addition of 0.1 mL of KRH buffer and 2-deoxy-D-[3H] glucose (0.2 Ci/mL with a specific activity of 10 Ci/mmol) and 5 mmol/L of glucose. Glucose uptake was terminated 30 minutes later by washing the cells 3 times with cold PBS. The cells were lysed overnight with 0.5 mol/L of NaOH and 0.1% SDS (weight/ volume). The radioactivity retained by cell lysates was determined by a scintillation counter (1 counts per minuteϭ0.888ϫ10 Ϫ12 Ci; Beckmann LC 6000IC) and normalized to protein content. 35 
Data Analysis
Data were meanϮSEM. Statistical comparison was performed by a 1-way ANOVA (2-way ANOVA for intraperitoneal glucose tolerance test) followed by the Tukey post hoc test. Significance was set at PϽ0.05.
Results

General Features, ROS, Mitochondrial Function, and Echocardiographic Properties of Low-and High-Fat-Fed Mice
High-fat diet feeding significantly increased body and organ (heart, liver, and kidney) weights, as well as heart:tibial length ratio in both FVB and IGF-1 mice. IGF-1 overexpression itself increased heart weight and heart:tibial length ratio, with an additional rise after high-fat diet feeding. Neither high fat diet nor IGF-1 transgene affected tibial length. As reported, 25 plasma and cardiac tissue IGF-1 levels were much higher in IGF-1 transgenic mice compared with FVB counterparts. High-fat diet feeding led to a significant decrease in plasma and cardiac tissue levels of IGF-1, the effect of which was masked by IGF-1 overexpression. Plasma insulin, homeostasis model assessment-insulin resistance, leptin, interleukin 6, and triglyceride levels were significantly elevated in high-fat diet-fed FVB and IGF-1 mice, the effects of which were not altered by IGF-1 overexpression. Blood pressure (diastolic and systolic) and heart rate were comparable among all of the groups, regardless of the diet regimen and IGF-1 levels (Table) . A cohort of high-fat diet-fed mice (3 FVB and 2 IGF-1) failed to gain enough final body weight (Ͻ115% of the low fat group average) and was considered as low responders. These low responders displayed subtle although significant increases (however much less than high responders) in plasma markers ( Figure S1 in the online-only Data Supplement). Our previous evidence suggested that high-fat diet feeding in the absence of obesity does not result in cardiac contractile dysfunction, 36 thus the low responders were not studied further. High-fat diet feeding significantly increased wall thickness, end-diastolic diameter, end-systolic diameter, and left ventricular LV mass (absolute weight but not the normalized value to body weight), indicating the presence of cardiac hypertrophy. IGF-1 overexpression significantly increased both absolute and normalized left ventricular mass without affecting wall thickness, end-systolic diameter, and end-diastolic diameter in low-fat-fed mice or any indices in the high-fat diet group. Interestingly, high-fat diet feeding depressed fractional shortening in FVB but not IGF-1 mouse hearts (Table) .
As shown in Figure 1 , the serum glucose levels in the low-fat diet-fed mice started to decline after peaking at 15 minutes, and nearly returned to baseline by 120 minutes after the intraperitoneal glucose challenge. However, the postchallenge glucose levels remained at much higher levels between 15 and 120 minutes in the high-fat-fed FVB and IGF-1 mice, indicating the systematic glucose intolerance. Calculation of area under the intraperitoneal glucose tolerance test curve further confirmed the presence of glucose intolerance in high-fat diet-fed FVB and IGF-1 mice. Nonetheless, the basal fasting glucose levels were similar in all of the groups, excluding the existence of full-blown diabetes mellitus. Furthermore, IGF-1 overexpression ablated the high-fat dietinduced occurrence of ROS accumulation, protein damage (carbonyl formation), apoptosis (caspase 3 activity), loss of myocardial ATP content, and mitochondrial damage (reduced aconitase activity and increased mitochondrial cytochrome C release shown as the transfer of cytochrome C from mitochondria into cytosol). IGF-1 overexpression itself had little effect on these glucose tolerance and cell damage indices.
Cardiomyocyte Contractile and Intracellular Ca 2؉ Properties Figure 2 depicts that neither a high-fat diet nor IGF-1 overexpression affected resting cell length. High-fat intake significantly reduced peak shortening (PS) and maximal velocity of shortening/relengthening (ϮdL/dt), as well as prolonged time-to-90% relengthening without affecting time to PS in FVB cardiomyocytes, reminiscent of earlier findings. 9 Importantly, IGF-1 abolished high-fat diet feedinginduced mechanical abnormalities without eliciting any notable effect by itself. In addition, data presented in Figure 3 reveal a significantly depressed peak and rise in intracellular Ca 2ϩ in response to electric stimulus (⌬fura-2 fluorescence intensity [FFI]), as well as intracellular Ca 2ϩ decay, along with unchanged baseline intracellular Ca 2ϩ in cardiomyocytes from high-fat-fed mice. IGF-1 overexpression negated high-fat diet-induced prolongation in intracellular Ca 2ϩ decay and depressed peak FFI and ⌬FFI with little effect on baseline FFI. IGF-1 transgene itself did not affect the intracellular Ca 2ϩ indices tested.
Effect of High-Fat Diet and IGF-1 on Stimulus Frequency-to-PS Relationship
Mouse hearts beat at high frequencies (Ͼ400/min). To investigate possible derangement of cardiac excitation-contraction coupling at higher frequencies, the stimulating frequency was increased stepwise from 0.1 to 5.0 Hz (300 bpm). Cells were initially stimulated to contract at 0.5 Hz for 5 minutes to ensure a steady state before commencing the frequency protocol. All of the recordings were normalized to PS obtained at 0.1 Hz of the same cell. Myocytes from high-fat diet FVB mice exhibited significantly exaggerated depression in PS at Ն1.0 Hz. IGF-1 transgene itself exerted little effect at all of the frequencies tested. However, it significantly lessened or prevented high-fat diet-induced depression in PS ( Figure 3A) .
Effects of IGF-1 on High-Fat Diet-Induced Apoptosis and Cardiac Hypertrophy
To examine the potential mechanism(s) behind IGF-1-elicited protection against high-fat diet-induced cardiac dysfunction, apoptosis and histology were examined in myocardium from FVB and IGF-1 mice fed a low-or high-fat diet using TUNEL and lectin staining, respectively. Results shown in Figure 4A through 4I indicate that the TUNEL-positive cells were more abundant in high-fat diet-fed FVB mice, the effect of which was significantly attenuated by IGF-1 overexpression. IGF-1 itself did not affect myocardial apoptosis. Consistently, Western blot data depict significantly enhanced proapoptotic protein Bax and Bad phosphorylation associated with downregulated antiapoptotic protein Bcl-2 and comparable Bad levels after high-fat diet feeding ( Figure S2 ). Although IGF-1 overexpression alone did not affect levels of Bax, Bcl-2, and Bad (or its phosphorylation), it nullified high-fat diet-induced changes in Bax, Bcl-2, and Bad phosphorylation. Our data further revealed accumulation of the lipid peroxidation end product malondialdehyde and the proinflammatory marker TNF-␣ after high-fat diet feeding. Although IGF-1 overexpression itself did not exert any notable effect on lipid peroxidation and TNF-␣ accumulation, it prevented highfat diet-induced lipid peroxidation but not TNF-␣ accumulation, suggesting a possible role of lipid peroxidation but unlikely inflammation in IGF-1-offered cardioprotective effects. Our histological data displayed in Figure 4J and 4K revealed equally enlarged cardiomyocyte cross-sectional areas in high-fat dietfed FVB and IGF-1 mice. Interestingly, IGF-1 transgene significantly enhanced cardiomyocyte area in the absence of high-fat diet intake. These findings are in line with the observation that high-fat diet and IGF-1 overexpression significantly upregulated expression of the hypertrophic maker nuclear factor of activated T cells c3 with little additive effect between the two ( Figure S3 ).
Expression of UCP-2, PGC1␣, SERCA2a, Na
؉
-Ca 2؉ Exchanger, and Phospholamban
To explore the possible mechanism behind IGF-1 and highfat diet-induced responses on cardiac function, in particular, mitochondrial function and intracellular Ca 2ϩ homeostasis, Western blot was performed to assess the levels of the key mitochondrial protein UCP-2 and PGC1␣, 17 as well as the essential intracellular Ca 2ϩ regulatory proteins SERCA2a, Na ϩ -Ca 2ϩ exchanger, and phospholamban. 29 Our data shown in Figure 5 depict that high-fat diet feeding significantly downregulated the expression of UCP-2, PGC1␣, SERCA2a, and Na ϩ -Ca 2ϩ exchanger, while upregulating the level of phospholamban in FVB mice. Although IGF-1 transgene itself did not alter the expression of UCP-2, PGC1␣, SERCA2a, Na ϩ -Ca 2ϩ exchanger, and phospholamban, it nullified high-fat diet-induced changes in UCP-2, PGC1␣, SERCA2a, Na ϩ -Ca 2ϩ exchanger, and phospholamban. Given that protein quality control through proteosomal degradation plays an essential role in cardiac homeostasis, including regulation of mitochondrial and intracellular Ca 2ϩ function, 23 expression of ubiquitin was examined. Our result failed to detect any change in the level of ubiquitin under high-fat diet feeding, IGF-1 overexpression, or both ( Figure S2 ), not favoring a role of the ubiquitin-proteasome system in high-fat diet and IGF-1 overexpression-induced myocardial geometric and function changes.
Western Blot Analysis for Receptors for Insulin and IGF-1, IRS, Akt, GSK3␤, Foxo3a, and mTOR Signaling
To examine possible signaling mechanism(s) involved in IGF-1-offered cardioprotection against high-fat diet-induced myocardial anomalies, expression and phosphorylation of insulin receptor-␤ and postreceptor signaling including IRS (both tyrosine and serine phosphorylation), Akt, and the Akt downstream signaling molecules GSK3␤, Foxo3a, and mTOR, were evaluated. Western blot findings shown in Figure 6A through 6D revealed that neither high-fat diet feeding nor IGF-1 overexpression affected the expression of insulin receptor-␤. High-fat diet feeding (but not IGF-1) led to an elevated basal phosphorylation of insulin receptor-␤ in both mouse groups. Given the potential cross-reactivity 
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between insulin and IGF-1 receptors, 18 expression and phosphorylation of IGF-1 receptor-␤ was also evaluated. High-fat diet feeding failed to alter IGF-1 receptor-␤ expression, whereas IGF-1 overexpression led to a significant downregulation of IGF-1 receptor-␤ regardless of the diet-feeding regimen. Tyrosine phosphorylation levels of insulin and IGF-1 receptor-␤ were examined in cardiomyocytes with insulin or IGF-1 stimulation (100 nmol/L). IGF-1 overexpression (but not high-fat diet) promoted basal phosphorylation of IGF-1 receptor-␤. Insulin stimulation elicited a robust phosphorylation in insulin receptor-␤ compared with exogenous IGF-1 stimulation. To the contrary, phosphorylation of IGF-1 receptor-␤ was more pronounced in response to IGF-1 compared with insulin. High-fat diet nearly obliterated insulin-or IGF-1-stimulated rise in insulin receptor-␤ phosphorylation. Although IGF-1 overexpression itself did not affect the stimulated insulin receptor-␤ phosphorylation, it partially restored high-fat diet-induced loss in insulin (but not exogenous IGF-1)-stimulated insulin receptor-␤ phosphorylation. Neither high-fat diet nor IGF-1 overexpression affected insulin-stimulated IGF-1 receptor-␤ phosphorylation. IGF-1 overexpression resulted in a drastic increase in the IGF-1 receptor ␤ phosphorylation that was comparable in both diet groups. Interestingly, the exogenous IGF-1-stimulated rise in IGF-1 receptor-␤ phosphorylation was more pronounced in IGF-1 mice. To examine the postreceptor signaling, IRS, Akt, GSK3␤, Foxo3a, and mTOR were evaluated. Data shown in Figure 6E and 6F reveal that IGF-1 overexpression (but not high-fat diet feeding) significantly elevated basal IRS tyrosine 1146 phosphorylation, which is the key to sensitize insulin signaling. 19 On the other hand, high-fat diet feeding (but not IGF-1 overexpression) significantly enhanced the basal serine 307 phosphorylation of IRS, which negatively regulates insulin signaling. 20 High-fat diet attenuated and facilitated the insulin-stimulated tyrosine and serine phosphorylation of IRS, respectively, the effects of which were attenuated or ablated by IGF-1 transgene. IGF-1 overexpression alone did not affect insulin-stimulated tyrosine or serine phosphorylation of IRS. Furthermore, neither high-fat diet nor IGF-1 overexpression affected the expression of Akt and GSK3␤ with or without insulin stimulation (data not shown). IGF-1 overexpression but not high-fat diet promoted basal phosphorylation of Akt and GSK3␤. More importantly, high-fat diet feeding overtly dampened insulinstimulated phosphorylation of Akt and GSK3␤, the effect of which was mitigated by IGF-1 overexpression ( Figure 7A and 7B). We further examined the Akt downstream signaling molecules Foxo3a and mTOR in FVB and IGF-1 hearts after high-fat diet feeding. Our immunoblotting data shown in Figure 7C and 7D revealed that high-fat diet, but not IGF-1, significantly upregulated the expression of Foxo3a in the presence or absence of insulin stimulation, the effect of which was significantly attenuated by IGF-1. However, expression of mTOR was unaffected by high-fat diet or IGF-1 regardless of the insulin stimulation status (data not shown). Neither high-fat diet nor IGF-1 transgene affected the basal phosphorylation of Foxo3a. Interestingly, IGF-1 overexpression but not high-fat diet led to an upregulation in basal mTOR phosphorylation. Consistent with its response in Akt phosphorylation, high-fat diet feeding significantly lessened insulin-stimulated phosphorylation of Foxo3a and mTOR, the effect of which was ablated by IGF-1 overexpression. Last but not least, IGF-1 overexpression alone did not affect insulin-stimulated phosphorylation of Foxo3a and mTOR. To evaluate whether changes in protein phosphatase play a role in altered insulin signaling, myocardial expression of PP2A and PP2B was examined in FVB and IGF-1 mice after lowor high-fat diet feeding. Our data depicted that high-fat diet upregulated expression of PP2A but not PP2B. Although IGF-1 overexpression did not affect the expression of protein phosphatases, it prevented high-fat diet-induced response in protein phosphatases ( Figure S3 ).
Influence of Exogenous IGF-1 Treatment on High-Fat Diet-Induced Cardiac Contractile Dysfunction
To examine whether exogenous IGF-1 supplementation influences high-fat diet-induced cardiac anomalies, low-fat and high-fat-fed FVB mice were supplemented with IGF-1 (3 mg/kg per day, IP) for 8 weeks after 3 months of respective diet feeding. Our data revealed that exogenous IGF-1 treatment significantly alleviated high-fat diet-induced changes in left ventricular end-systolic diameter and fractional shortening but not body weight, left ventricular end-diastolic diameter, left ventricular wall thickness, and left ventricular mass (absolute or normalized; Figure S4 ). Further scrutiny of cardiomyocyte function revealed that IGF-1 treatment significantly attenuated or ablated high-fat diet-induced cardiomyocyte dysfunction (decreased PS and ϮdL/dt, prolonged time-to-90% relengthening with unchanged time to PS; Figure S5) . IGF-1 supplementation failed to alter echocardiographic or cardiomyocyte function in low-fat diet-fed mice.
Influence of IGF-1 on Palmitate-Induced Responses in Glucose Uptake, Mitochondrial Function, Cell Survival, and Cardiomyocyte Contractile Properties
To further examine the causal relationships in IGF-1-offered protection against high-fat diet-induced defect in mechanical, mitochondrial, and insulin responses, cardiomyocytes from control FVB mice were exposed to palmitate (100 mol/L) in the absence or presence of IGF-1 (10 nmol/L), the mitochondrial uncoupler carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) (1 mol/L), or the GSK3␤ inhibitor SB216763 (10 mol/L) for 6 hours. relengthening), the effect of which was abolished by IGF-1. Interestingly, both FCCP and SB216763 mitigated IGF-1-induced beneficial effects. No additive effect was observed between palmitate and the pharmacological inhibitors.
Discussion
The salient findings of our study are that high-fat diet feeding elicits glucose intolerance, reduced IGF-1 levels, cardiac hypertrophy, enhanced ROS accumulation, myocardial contractile dysfunction, impaired intracellular Ca 2ϩ handling, apoptosis, protein, and mitochondrial damage (cytochrome C release and loss of myocardial ATP). These myocardial geometric, functional, and mitochondrial changes were associated with dampened insulin-stimulated phosphorylation of insulin receptor-␤ (but not IGF-1 receptor ␤), IRS-1 (tyrosine residue), Akt, GSK3␤, Foxo3a (pan Foxo3a expression), and mTOR, along with increased serine phosphorylation of IRS. Intriguingly, high-fat diet-induced functional and mitochondrial aberrations were significantly attenuated or nullified by IGF-1 despite persistent cardiac hypertrophy. Exogenous IGF-1 supplementation mimicked IGF-1 transgene-induced beneficial effects against high-fat diet-induced cardiac contractile dysfunction. In vitro study revealed that IGF-1 prevents against palmitate-induced adverse effect on glucose uptake, cell survival, mitochondria, and cardiomyocyte dysfunction through a GSK-3␤ and mitochondria-dependent mechanism. These data suggest that IGF-1 may elicit beneficial cardiac contractile effects against high-fat diet feeding, possibly via improved cell survival and mitochondrial function, as well as insulin receptor and postreceptor signaling.
High-fat diet intake triggers hyperlipidemia, hyperleptinemia, hyperinsulinemia, insulin resistance, elevated circulating cytokine, obesity, hypertension, and type 2 diabetes mellitus, 8, 37 which are considered major risk factors for myocardial remodeling and dysfunction via sympathetic overactivation, renin-angiotensin stimulation, or intrinsic myopathic changes. 1,3 Our fat-feeding regimen elicited elevated plasma markers for insulin, leptin, triglycerides, and cytokines, with little changes in blood pressure and blood glucose, thus not favoring a major role of concomitant hypertension and diabetes mellitus to high-fat feeding-induced anomalies. In particular, IGF-1 did not exert any discernible "systemic effect" on body weight, glucose metabolism, and plasma insulin, homeostasis model assessment-insulin resistance, leptin, interleukin 6, or triglyceride levels, nor did the growth factor alter myocardial TNF-␣ levels in obesity, suggesting that the IGF-1-induced beneficial effect is not secondary to changes in systemic metabolic profile. In our hands, high-fat diet feeding increased heart weight in both FVB and IGF-1 mice, indicating a more predominant effect of high-fat diet intake than IGF-1 on cardiac remodeling.
In this study, we observed compromised cardiac geometry and function (reduced fraction shortening, enlarged end-diastolic diameter, end-systolic diameter, wall thickness, depressed PS, ϮdL/dt, and prolonged time-to-90% relengthening) after high-fat diet feeding, consistent with previous findings. 9 High-fat diet-induced obesity was also found to prolong shortening duration (time to PS), 7 disparate from our current observation. It is possible that use of difference species and duration of fat diet feeding may play a role in such discrepancy. Impaired intracellular Ca 2ϩ handling (reduced intracellular Ca 2ϩ clearance, peak, and rise in intracellular Ca 2ϩ rise) may underscore prolonged relaxation, reduced PS, maximal velocity of relengthening, and fractional shortening found in high-fat diet-fed mouse hearts. Our observation of a steeper decline in contractile amplitude with increased stimulus frequencies in high-fat-fed mice is also supportive of the dampened intracellular Ca 2ϩ recycling capacity. The fact that IGF-1 transgene reconciled high-fat diet-induced intracellular Ca 2ϩ mishandling along with ROS accumulation and lipid peroxidation favors a role of oxidative stress in IGF-1-induced responses, similar to the beneficial effect of the antioxidant metallothionein in sucrose or highfat diet-induced insulin resistance models. 9, 26 This is also in line with our earlier report that cardiac overexpression or supplementation of IGF-1 prevents against diabetes mellitusinduced cardiac mechanical defects through improved intracellular Ca 2ϩ homeostasis and redox status. 29, 38 Enhanced . Western blot analysis of the mitochondrial proteins uncoupling protein 2 (UCP-2) and peroxisome proliferator-activated receptor-␥ coactivator 1␣ (PGC1␣), as well as the Ca 2ϩ regulatory proteins sarco(endo) plasmic reticulum Ca 2ϩ-ATPase (SERCA2a), Na ϩ -Ca 2ϩ exchanger (NCX), and phospholamban in myocardium from low-fat (LF) and high-fat (HF)-fed FVB and insulin-like growth factor 1 (IGF-1) mice. A, Representative gel blots of UCP-2, PGC1␣, SERCA2a, Na ϩ -Ca 2ϩ exchanger, phospholamban, and GAPDH (loading control) using specific antibodies. B, UCP-2. C, PGC1␣. D, SERCA2a. E, Na ϩ -Ca 2ϩ exchanger. F, Phospholamban. All of the proteins were normalized to the loading control GAPDH. MeanϮSEM, nϭ8 to 9 mice per group, *PϽ0.05 vs FVB-LF group, #PϽ0.05 vs FVB-HF group. oxidative stress as seen in our high-fat diet model is a major risk factor for cardiac remodeling, intracellular Ca 2ϩ , and contractile anomalies. 39 Furthermore, our observation that IGF-1 restored downregulated expression of SERCA2a and Na ϩ -Ca 2ϩ exchanger, as well as upregulated phospholamban after high-fat diet feeding, also supported a role of intracellular Ca 2ϩ homeostasis in IGF-1-offered protection. Data from our study failed to detect any notable change in ubiquitin expression after high-fat diet feeding, reminiscent of our earlier report using the same obesity model. 36 The ubiquitin proteasome is a barrel-shaped protease capable of recognizing and destroying proteins decorated with Ն4 ubiquitin residues. 23 Our findings did not favor a role of ubiquitinassociated protein degradation in cardiac anomalies after high-fat diet intake. Likewise, our data also revealed little roles of cytokines (TNF-␣ and interleukin 6) in IGF-1-offered beneficial effect against cardiac dysfunction, apoptosis, and mitochondrial damage after high-fat diet feeding.
One significant finding from our study is that IGF-1 prevented high-fat diet-or palmitate-induced insulin signaling loss, protein, and mitochondrial damage, as well as apoptosis. Mitochondrial damage has been observed after high-fat diet intake, insulin resistance, and type 2 diabetes mellitus. 4, 40 It is possible that high-fat diet-induced downregulation of PGC1␣ and UCP-2 may underscore mitochondrial damage (cytochrome C release, reduced aconitase ac- GAPDH 37KD Insulin (100 nM) Figure 7 . Phosphorylation of Akt, glycogen synthase kinase 3␤ (GSK3␤), forkhead transcriptional factors (Foxo3a), and mammalian target of rapamycin (mTOR) with or without insulin stimulation (100 nmol/L for 15 minutes) in cardiomyocytes from low-fat (LF) and high-fat (HF)-fed FVB and insulin-like growth factor 1 (IGF-1) mice. A, phosphorylated Akt:Akt ratio. B, phosphorylated GSK3␤:GSK3␤ ratio. C, phosphorylated Foxo3a:Foxo3a ratio. D, phosphorylated mTOR:mTOR ratio. Insets, Representative gel blots of pan and phosphorylated Akt, GSK3␤, Foxo3a, and mTOR (GAPDH was used as loading control) using specific antibodies. MeanϮSEM, nϭ6 to 9 isolations per group, *PϽ0.05 vs unstimulated FVB-LF group, †PϽ0.05 vs insulin-stimulated FVB-LF group, #PϽ0.05 vs respective FVB-HF group.
tivity, and loss of ATP), as reported earlier using the same obesity model. 9 PGC1␣ is essential to physiological heart function, because PGC1␣ knockout or deficiency leads to diminished cardiac function and heart failure. 41, 42 Therefore, decreased PGC1␣ expression found in our study may reflect a maladaptive response after high-fat diet feeding. Although the precise cellular mechanism behind the downregulated PGC1␣ after high-fat diet intake is not entirely clear, it is noteworthy that certain posttranslational modifications, such as oxidative modification, may play a role. 41 Deacetylation of PGC1␣ through Sirt has been shown to alter PGC1␣ activity on gluconeogenic gene transcription. 41, 43 Furthermore, our data revealed a reduced level of UCP-2, which may mediate PGC1␣-stimulated mitochondrial biogenesis and respiration, as well as control of ROS production. 15, 16 The fact that IGF-1 transgene may offset downregulated UCP-2 and PGC1␣ favors a possible role of mitochondrial function and oxidative stress in the regulation of myocardial contractile function, consistent with the findings of ROS production, apoptosis, and protein carbonyl formation. As mentioned earlier, IGF-1 may offer protection against diabetic cardiomyopathy via alleviating oxidative damage, 38 although further study is warranted to define the interplay responsible for IGF-1-induced regulation on PGC1␣ and UCP-2 expression, as well as mitochondrial integrity or content after high-fat diet feeding.
Data from our study suggest that IGF-1 improved the dampened insulin-stimulated glucose uptake, phosphorylation of insulin receptor-␤, IRS (Tyr1146), and the postreceptor signals (Akt, Foxo3a, GSK3␤, and mTOR) after high-fat diet or palmitate exposure. Serine phosphorylation of IRS, which is associated with mitochondrial damage in diabetes mellitus, 20, 40 may play a key role in IGF-1-and high-fat diet-induced regulation of insulin signaling. Unlike insulin receptor, our immunoprecipitation results do not support the presence of compromised IGF-1 receptor phosphorylation (in response to insulin or IGF-1). Biological actions of insulin and IGF-1 are transduced through the insulin and IGF-1 receptors, with high structural homology and cross-reactivity between the two. 18 Our findings suggest that IGF-1 overexpression may prevent dampened insulin signaling in high-fat diet-induced obesity through IGF-1 receptor phosphorylation. Given that insulin and IGF-1 share similar postreceptor signaling pathways, IGF-1 may bypass the membrane insulin receptor by exerting its biological actions through the IGF-1 receptor or the insulin-IGF-1 receptor hybrid to turn on postinsulin receptor signaling. 17, 18 Akt and mTOR are key signaling factors with reduced activation contributing to apoptosis and cardiac dysfunction. 44 Our data revealed that high-fat diet lessened insulin-stimulated phosphorylation of the Akt downstream signaling molecules Foxo3a, GSK3␤, and mTOR. We found that high-fat diet significantly reduced the proapoptotic transcriptional factor Foxo3a inactivation (phosphorylation), the effect of which was nullified by IGF-1. Our observation of reduced Foxo3a phosphorylation coincides with the enhanced apoptosis (elevated caspase-3 activity, TUNEL, Bax, and Bad phosphorylation along with reduced Bcl-2 expression) after high-fat diet feeding. The decrease in the insulin-stimulated phosphorylation of Foxo3a, GSK3␤, and mTOR may be resulted from dampened Akt phosphorylation. GSK-3␤, a serine/threonine kinase downstream of Akt inactivated by phosphorylation of Ser9 by oxidative stress, serves as a negative regulator of cardiac hypertrophy and mitochondrial function through mitochondrial permeation pore opening. 45 Data from our study revealed that IGF-1 prevented high-fat diet or palmitateinduced changes in GSK3␤ phosphorylation, aconitase activity, cell survival, and cytochrome C release, favoring a role of the GSK3␤-mitochondrial cascade in IGF-1-offered cardioprotection. In our hands, basal phosphorylation of Akt, GSK3␤, and mTOR was enhanced in IGF-1 transgenic mice, regardless of diet regimen. These observations suggest that IGF-1 offers cardioprotection against fat-diet feeding through improved mitochondrial function en route to preserved insulin signaling and cell survival despite persistent cardiac remodeling resulted from its growth promoting ability (Figure S6 ). Our data also revealed a possible role of the insulin signaling degrading phosphatases, 21 in particular PP2A, in IGF-1-offered protection against high-fat diet-induced cardiac anomalies, although further study is needed to delineate the role of protein phosphatase in compromised insulin signaling associated with obesity.
Perspectives
Our present work has provided evidence that IGF-1 prevents myocardial contractile dysfunction, apoptosis, protein, and mitochondrial damage in high-fat diet-induced obesity possibly through regulation of mitochondrial function and insulin signaling. These results have consolidated a role for IGF-1 in the maintenance of cardiac physiology and, more importantly, the therapeutic value of IGF-1 against aberrant myocardial function and remodeling in obesity. Furthermore, it prompts the speculation that changes in IGF-1 levels in certain cardiovascular diseases may account, at least in part, for the increased cardiac pathology under these conditions. Future work should focus on the regulation of mitochondrial function in obesity so that optimal therapeutic strategy may be sought for obesity-related cardiomyopathy and cardiac remodeling.
*These authors contributed equally to this work
MATERIALS AND METHODS
Experimental animals, high fat diet feeding, exogenous IGF-1 treatment and intraperitoneal glucose tolerance test (IPGTT): The experimental procedure described here was approved by the Institutional Animal Use and Care Committee at the University of Wyoming (Laramie, WY). In brief, 2-3 month-old male FVB and cardiomyocyte-specific IGF-1 overexpression transgenic mice were randomly assigned to low fat (10 and 70% of total calorie from fat and carbohydrate, respectively, catalogue #D12450B) or high fat (45 and 35% of total calorie from fat and carbohydrate, respectively, catalogue #D12451) diets from Research Diets Inc (New Brunswick, NJ) for 5 months. The high fat diet was calorically rich (4.83 kcal/g vs. 3 .91 kcal/g in low-fat diet) due to higher fat composition. However, the two diets possessed similar nutrient composition. Generation of cardiomyocyte-specific IGF-1 overexpression transgenic mice using the α-myosin heavy chain (MHC) promoter was previously described in detail. 1 The fur pigmentation was used as a marker for IGF-1 (light brown) or FVB (white) mouse identification. For exogenous IGF-1 treatment, a group of low fat and high fat-fed FVB mice was supplemented with the recombinant IGF-1 (3 mg/kg/d, i.p., National Hormone and Peptide Program, NIDDK) for 8 weeks 2 after being placed on low and high fat diets for 3 months. The IGF-1-treated mice were kept on their respective low or high fat diet for the entire duration (8 weeks) of IGF-1 supplementation. Mice were housed individually in a climate-controlled environment with a 12/12-light/dark cycle and free access to diets and water. After 5 months of feeding, all mice fasted for 12 hrs were given an intraperitoneal injection of glucose (2 g/kg b.w.). Blood samples were drawn from the tail vein immediately before glucose challenge, as well as 15, 60 and 120 min thereafter. Serum glucose levels were determined using an Accu-Chek III glucose analyzer. 3 The area under the curve (AUC) was calculated using trapezoidal analysis for each adjacent time point and serum glucose level. Blood pressure was recorded using a CODA non-invasive blood pressure system (Kent Scientific Co, Torrington, CT) according to the instructions and reported values were averaged from 3 readings each mouse. 4 Blood insulin, leptin, interleukin-6 (IL-6), IGF-1 and triglycerides levels were measured using mouse insulin, leptin, IL-6, IGF-1 and triglyceride ELISA commercial kits from Diagnostic System Laboratory (Webster, TX) and Pierce Biotechnology (Rockford, IL). 4, 5 The homeostasis model assessment of insulin resistance (HOMA-IR) was used to estimate insulin resistance based on the following equation: fasting insulin (µU/ml) x fasting blood glucose (mmol/l)/22.5. 6 2 Measurement of tissue IGF-1 levels: Myocardial IGF-1 levels were determined using our previously described procedure. 5 Briefly, lyophilized myocardial tissues were pulverized and duplicate aliquots were extracted with 1 M acetic acid by end-to-end rotation for 4 hrs at 4°C. The extraction mixtures were centrifuged. IGF-1 concentration of the supernatant was determined using a competitive binding enzyme immunoassay kit (Diagnostic Systems) after pre-treatment to remove IGF-1 binding proteins. The recovery of an internal standard of IGF-1 added at the beginning of the extraction procedure was approximately 99%. The inter-assay and intra-assay variability is 4.9-11.9% and 5.3-9.1%, respectively.
Echocardiographic assessment: Cardiac geometry and function were evaluated in anesthetized (Avertin 2.5%, 10 μl/g b.w., i.p.) mice using a 2-D guided M-mode echocardiography (Sonos 5500, Phillips Medical System, Andover, MA) equipped with a 15-6 MHz linear transducer. Left ventricular (LV) wall thickness, diastolic and systolic LV dimensions were recorded from the Mmode images. Fractional shortening was calculated from end-diastolic diameter (EDD) and endsystolic diameter (ESD) using the equation of (EDD-ESD)/EDD. Estimated echocardiographic LV mass was calculated as [(LVEDD + septal wall thickness + posterior wall thickness) 3 -LVEDD 3 ]*1.055, where 1.055 (mg/mm 3 ) represents the density of myocardium. Heart rates were averaged over 10 cardiac cycles.
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Isolation of murine cardiomyocytes: After ketamine/xylazine sedation, hearts were removed and perfused with Krebs-Henseleit bicarbonate (KHB) buffer containing (in mM): 118 NaCl, 4.7 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , 10 HEPES and 11.1 glucose. Hearts were digested with collagenase D (223 U/ml) for 20 min. Left ventricles were removed and minced before being filtered. Myocyte yield was ~ 75% which was not affected by high fat diet or IGF-1 overexpression. Only rod-shaped myocytes with clear edges were selected for mechanical study. 3 To examine the causal relationship in IGF-1-induced actions in mechanical and mitochondrial responses, cardiomyocytes from FVB mice were maintained in a DMEM culture medium while being treated with palmitate (100 μM) at 37 o C for 6 hrs in the absence or presence of IGF-1 (10 nM), the mitochondrial uncoupler FCCP (1 μM), or the GSK3β inhibitor SB216763 (10 µM) prior to mechanical or biochemical assessment.
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Cell shortening/relengthening: Mechanical properties of cardiomyocytes were assessed using a SoftEdge MyoCam® system (IonOptix Corporation, Milton, MA). In brief, cells were placed in a Warner chamber mounted on the stage of an inverted microscope (Olympus, IX-70) and superfused (~1 ml/min at 25 °C) with a buffer containing (in mM): 131 NaCl, 4 KCl, 1 CaCl 2 , 1 MgCl 2 , 10 glucose, 10 HEPES, at pH 7.4. The cells were field stimulated with supra-threshold voltage at a frequency of 0.5 Hz (unless otherwise stated), 3 msec duration, using a pair of platinum wires placed on opposite sides of the chamber connected to a FHC stimulator (Brunswick, NE). The myocyte being studied was displayed on the computer monitor using an IonOptix MyoCam camera. An IonOptix SoftEdge software was used to capture changes in cell length during shortening and relengthening. Cell shortening and relengthening were assessed using the following indices: peak shortening (PS) -indicative of peak ventricular contractility, time-to-PS (TPS) -indicative of contraction duration, and time-to-90% relengthening (TR 90 ) -represents cardiomyocyte relaxation duration, maximal velocities of shortening (+dL/dt) and relengthening (−dL/dt) -indicatives of maximal velocities of ventricular pressure rise/fall. In the 
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